Optimal Strategies for Reducing Cardioembolic Risk in the Patient with Non-valvular Atrial Fibrillation
Several new pharmacologic agents indicated for the reduction of stroke risk in patients with non-valvular atrial fibrillation have been approved by the FDA since 2010 and additional agents are in development. The availability of these new classes of agents has exploded the information required of clinicians who care for these complex patients.
This program leverages the respective strengths of medicine, nursing, and pharmacy to educate you about a patient-centered approach to safely and effectively reducing stroke risk in the patient with non-valvular atrial fibrillation.
Credit: 2.25 CE (with 1 hour Pharmacology)
Upon Completion of this course, participants will be able to:
- Identify the factor(s) in the coagulation cascade on which warfarin, dabigatran, rivaroxaban and apixaban exert their respective anticoagulant effects
- Identify sources for evidence-based guidelines for antithrombotic therapy in the reduction of cardioembolic risk in the patient with non-valvular atrial fibrillation.
- Define the impact of renal function, clinical history, and patient age on the choice of anticoagulant agent
- Describe the role of effective clinician/patient communication in the safe management of oral anticoagulation
- Outline an efficient method of incorporating shared decision making when developing a treatment plan for the patient with NVAF